Q2 report due on Friday 14 July Estimates fine-tuned Q2e EBIT margin of 6.
Försening i tidslinjen... Egetis meddelade under onsdagskvällen att de förskjuter den planerade tids...
S2Medical har tagit fram en ny strategi där resurser läggs på befintliga produkter vilket ska bidra ...
Redeye was glad to see that Moberg Pharma received the EU approval within the indicated time frame.
Buys wooden furniture & components manufacturer Hedlunda Adds ~46% to PF EBITDA for '23e 3.
Candles aviserade i början av 2023 om en renodling av verksamheten samtidigt som tillväxtmålet om mi...
Q3 – fullt fokus på patientrekrytering Diamyd släppte under gårdagen sin Q3-rapport för det brutna r...
Ett förvärv som levererat Raketech förvärvade i augusti 2019 affiliatebolaget Casumba.
Redeye is positive about the last week’s strong order flow, which is highly important for the compan...
Redeye notes that the first hospital in the US trial with Emcitate (ReTRIACt) has been activated and...
Mendus has provided an update on its development plans for its lead cancer vaccine, vididencel, prim...
Redeye comments on the preliminary data from Spago Nanomedical’s clinical phase IIa trial SPAGOPIX-0...
Redeye comments on the EU approval of MOB-015 and the new two-step approach to the EU launch.
Det disruptiva teknikbolaget Luxbright AB (”Luxbright” eller ”Bolaget”) demokratiserar röntgenbransc...
AVTECH has announced an extension of its Southwest agreement, which holds a value of SEK38m-52m over...
We expect a bit weaker organic growth in Q2 We cut FCF by 6%, 4% and 6% for '23e, '24e and '25e Shar...
Scandinavian Astor Group (”Astor Group” eller ”bolaget”) meddelade den 26 juni att dotterbolaget Mar...
Redeye comments on the recent development involving Henrik Andersson, CEO of Northbaze Group, who ha...
Q2e: sales SEK 245m, EBITA 6.8%, EPS SEK 0.57 Expect order book realisation to continue, outlook pro...
Redeye initiates coverage of marketing technology company Eniro Group, seeing a compelling transform...
